A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

NCT06764836 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumors
HCC

Interventions

DRUG: IMM27M
DRUG: IMM2510

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.